A Multicenter Extension Trial of Subcutaneously Administered AIN457 in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Phase 2
- Conditions
- psoriasis
- Registration Number
- JPRN-jRCT2080221181
- Lead Sponsor
- ovartis Pharma K.K.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Patients who completed the core study ( A Multicenter Trial of Subcutaneously Administered AIN457 in Patients With Moderate to Severe Chronic Plaque-type Psoriasis)
Exclusion Criteria
-Patients who experience a second consecutive full relapse at visit 13 of the core study ( A Multicenter Trial of Subcutaneously Administered AIN457 in Patients With Moderate to Severe Chronic Plaque-type Psoriasis)
Other protocol-defined inclusion/exclusion criteria may apply
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety and tolerability as measured by Adverse Events and clinically significant changes in vital signs and clinical laboratory variables.
- Secondary Outcome Measures
Name Time Method ong-term efficacy as assessed by PASI 50, PASI 75 and PASI 90 achievement and an improvement of the IGA during the trial.